In This Article:
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
Whatever the consensus opinion may be, our team at StockStory cuts through the noise by conducting independent analysis to determine a company’s long-term prospects. That said, here is one stock poised to prove Wall Street wrong and two facing legitimate challenges.
Two Stocks to Sell:
BlackLine (BL)
Consensus Price Target: $56.91 (3.5% implied return)
Started in 2001 by software engineer Therese Tucker, one of the very few women founders who took their companies public, BlackLine (NASDAQ:BL) provides software for organizations to automate accounting and finance tasks.
Why Does BL Give Us Pause?
-
Customers had second thoughts about committing to its platform over the last year as its average billings growth of 7.4% underwhelmed
-
Estimated sales growth of 7.5% for the next 12 months implies demand will slow from its three-year trend
-
Expenses have increased as a percentage of revenue over the last year as its operating margin fell by 2.1 percentage points
At $55 per share, BlackLine trades at 5x forward price-to-sales. To fully understand why you should be careful with BL, check out our full research report (it’s free).
Avery Dennison (AVY)
Consensus Price Target: $190.83 (4% implied return)
Founded as Kum Kleen Products, Avery Dennison (NYSE:AVY) is a manufacturer of adhesive materials, display graphics, and packaging products, serving various industries.
Why Do We Steer Clear of AVY?
-
Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion
-
3.7 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position
-
Waning returns on capital imply its previous profit engines are losing steam
Avery Dennison’s stock price of $183.57 implies a valuation ratio of 17.8x forward P/E. If you’re considering AVY for your portfolio, see our FREE research report to learn more.
One Stock to Watch:
ResMed (RMD)
Consensus Price Target: $264.49 (4.3% implied return)
Founded in 1989 to address the then-underdiagnosed condition of sleep apnea, ResMed (NYSE:RMD) develops cloud-connected medical devices and software solutions that treat sleep apnea, COPD, and other respiratory disorders for home and clinical use.
Why Are We Positive On RMD?
-
Constant currency growth averaged 12% over the past two years, showing it can expand globally regardless of the macroeconomic environment
-
Additional sales over the last five years increased its profitability as the 15.7% annual growth in its earnings per share outpaced its revenue
-
Free cash flow margin jumped by 7.1 percentage points over the last five years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends